Shaanxi Kanghui Pharmaceutical (603139.SH) plans to contribute RMB35 million to establish a subsidiary, Wanhuashan Pharmaceutical.
Kanghui Pharmaceutical (603139.SH) announced that, in line with its strategy and business development needs, the company plans to contribute RMB35 million in cash to establish a wholly-owned subsidiary, Shaanxi Kanghui Wanhuashan Pharmaceutical Co., Ltd. ("Wanhuashan Pharmaceutical"). Wanhuashan Pharmaceutical's proposed registered capital is RMB35 million, with the company contributing RMB35 million, accounting for 100% of the registered capital. It will primarily engage in the research, development, production, and sales of pharmaceuticals, as well as the sales of food, health foods, cosmetics, and other businesses.
Shaanxi Kanghui Pharmaceutical (603139.SH) announced that, based on the company's strategy and business development needs, the company plans to contribute RMB35 million in cash to establish a wholly-owned subsidiary, Shaanxi Kanghui Wanhuashan Pharmaceutical Co., Ltd. ("Wanhuashan Pharmaceutical"). Wanhuashan Pharmaceutical's proposed registered capital is RMB35 million, with the company contributing RMB35 million, accounting for 100% of the registered capital. It will mainly engage in the research and development, production, and sales of pharmaceuticals; and the sales of food, health food, cosmetics, and other businesses.
Related Articles
NEWBORNTOWN (09911) repurchased 232,000 shares on November 4 for HK$1.9884 million.
COURAGE INV (01145) repurchased 180,000 shares for HK$22,300 on November 4.
TRULY INT'L (00732) repurchased 300,000 shares on November 4 for HK$243,000.
NEWBORNTOWN (09911) repurchased 232,000 shares on November 4 for HK$1.9884 million.
COURAGE INV (01145) repurchased 180,000 shares for HK$22,300 on November 4.
TRULY INT'L (00732) repurchased 300,000 shares on November 4 for HK$243,000.
